Why did 4882.T stock spike pre-market?

4882.T stock spiked on heavy volume, likely from speculative buying around pipeline news or block trades. No earnings release is scheduled until 2026-05-08, so confirm company releases and regulatory updates before acting.

What are the main risks for Perseus Proteomics (4882.T)?

Primary risks are clinical trial setbacks, funding and dilution, and binary news events. Financials show EPS **-53.23** and negative free cash flow per share, so watch for capital raises that can dilute holders.

What is Meyka AI’s short-term forecast for 4882.T?

Meyka AI's yearly projection for 4882.T is **JPY 290.11**, implying a **0.73%** upside from **JPY 288.00**. Forecasts are model-based projections and not guarantees.

How should traders approach 4882.T given the high volume?

Trade with strict risk limits and size positions for volatility. Use volume-confirmed breakouts, set stop-losses near **JPY 231.00**, and consider partial profit-taking near intraday resistance.

JP Stocks

4882.T Perseus Proteomics JPX +25.76% pre-market on 16.9M vol: monitor catalysts

ByHuzaifa Zahoor March 9, 2026March 9, 2026

4882.T stock surged 25.76% in pre-market trade to JPY 288.00 on 16,869,800.00 shares, marking one of its largest intraday volume spikes. Perseus Proteomics Inc. (4882.T) led early JPX activity as traders reacted to a high-liquidity move. The jump followed a breakout above the 50-day average of JPY 235.24 and the stock opened at JPY 231.00. We examine catalysts, valuation, technicals and Meyka AI’s short-term forecast to help frame trading and risk in Japan’s healthcare sector.